Ardea Biosciences — Corporate Update (March 2010)
27 slides from Ardea Biosciences's corporate update, Mar 8, 2010
Slide 1: Company Update
) Biosciences Designing Solutions for Serious Diseases Company Update March 8, 2010
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results
Slide 3: Status of Development Programs
Status of Development Programs RDEA427 RDEA806 900 Series Discovery Preclinical Phase 0/1 Phase 2 A B Phase 3 NNRTI for HIV NNRTI for HIV MEKI for cancer 3 Gout RDEA594 RDEA684 MEKI + sorafenib for cancer RDEA119 Gout RDEA119 3rd Gen NNRTIs
Slide 4: Gout/Hyperuricemia
Gout/Hyperuricemia Ardea) Biosciences
Slide 5: Refractory Disease Has Not Disappeared
Refractory Disease Has Not Disappeared 5
Slide 6: Hyperuricemia/Gout - Unmet Medical Need
Hyperuricemia/Gout - Unmet Medical Need Gout is caused by abnormally elevated levels of uric acid (>6.8 mg/dL) Painful and debilitating disease with attacks of severe pain/inflammation and disfiguring nodules (tophi) Increasing incidence and severity in U.S. (> 5,000,000 potential patients) with $11
Slide 7: Global Incidence of Gout and Hyperuricemia
Global Incidence of Gout and Hyperuricemia 7 Prevalence Hyperuricemia Prevalence Gout Gout Pts Diagnosed Gout Pts on ULT Source: Hyperuricemia - Estimates based on rates in NHANES I-III; Gout -Decision Resources ~57 MM 19.7 MM 14.5 MM 7.8 MM Millions of Patients
Slide 8: Almost Half of Patients Under Treatment Are Still Having Flares
Almost Half of Patients Under Treatment are Still Having Flares - Lower sUA Reduces Flares 8 8 Proportion of Subjects (%) Abstract 758: MA Becker, et al. ACR Boston November 2007 Ardea Market Research
Slide 9: Uric Acid Production and Elimination
Hare, J. M. et al. Circulation 2003;107:1951-1953 Uric Acid Production and Elimination Allopurinol Febuxostat RDEA594 Probenecid Losartan (Cozaar(r)) Benzbromarone* 9 *Benzbromarone is a URAT1 inhibitor approved outside of the US and later withdrawn due to liver toxicity. Pegloticase URAT1 US Allopu
Slide 10: Competition: Probenecid (Benuryl) - Uricosuric
Competition: Probenecid (Benuryl) - Uricosuric Dosage: 500 mg BID to 500 mg QID Side Effects: Headache, anorexia, nausea, vomiting, diarrhea, abdominal discomfort, skin rash, flushing, drug fever, anaphylaxis, increased urination, sore gums, dizziness, hemolytic anemia, and aplastic anemia Significa
Slide 11: URAT1 Inhibitors Increase the Urinary Excretion of Uric Acid
>99% Reabsorption Excretion ~100% of uric acid is initially filtered through glomerular filtration URAT1 Inhibitors Increase the Urinary Excretion of Uric Acid URAT1 Enomoto; Urat1 identification in Nature May2002 D Levinson & L Sorensen; Renal Handling of Uric Acid Proximal Tubule Benzbromarone RDE
Slide 12: Selective URAT1 Transporter Inhibition for Hyperuricemia/Gout
12 Selective URAT1 Transporter Inhibition: An Important Contribution to the Treatment of Hyperuricemia/Gout Inhibition of the URAT1 transporter is a well-validated target for gout Benzbromarone has over 10 million patient-years of treatment experience, with very few side effects, except liver toxici
Slide 13: Combining RDEA594 with XO Inhibitor Should Accelerate Clearance of Urate
Diet & Metabolism <400 mg/day Diet & Metabolism 600-800 mg/day Joint Tophus 10 mg/dL 6 mg/dL serum level Xanthine Oxidase Inhibitor URAT1 Inhibitor <5 mg/dL Combining RDEA594 with XO Inhibitor Should Accelerate Clearance of Urate from Body Pools urine urine 200 mg/day 13 600 mg/day 300 mg/day gout p
Slide 14: RDEA594 Phase 2a Pilot Pharmacodynamic and Safety Study in Gout Patients
Arm 1:RDEA594 200 mg QD Screenin g Period Colchicine Treatment Randomize if no gout flare during 2 weeks of colchicine Off drug Off drug Arm 2: Placebo 400 mg QD Off drug Arm 3: Allopurinol 300 mg 5 pts 5 pts 11 pts 7-21 days 1 week 2 weeks total with dose escalation of RDEA594 after Week 1 1 week P
Slide 15: Phase 2a - Mean sUA Change from Baseline
Phase 2a - Mean sUA Change from Baseline N=5 N=5 N=5 Cohorts 1&2 combined Data excludes overproducers; trough samples out to Day 21. LOCF used for allopurinol due to incomplete data N=10 RDEA594 400 mg + Allopurinol produced a reduction of sUA from a mean of 10.2 mg/dL to 4.7 mg/dL, with 100% of pat
Slide 16: RDEA594 and Allopurinol Combination Product Under Development
RDEA594 and Allopurinol Combination Product Under Development Allopurinol 300 mg (Zyloprim) RDEA594 400 mg RDEA594 400 mg and Allopurinol 300 mg Reference Product, Tylenol (r) GelCap 16
Slide 17: Phase 2a - Urinary Excretion of Uric Acid
Phase 2a - Urinary Excretion of Uric Acid Gout patients RDEA594 normalizes uric acid excretion in gout patients with inadequate excretion Allopurinol reduces uric acid excretion even further in patients with already low excretion The combination of these two agents reduces production, but also incre
Slide 18: Phase 2a Adverse Events by Treatment Group
Treatment Group Mild Moderate Severe Serious Adverse Event Treatment Group (grade 1) (grade 2) (grade 3) Serious Adverse Event Treatment Group N Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Number of Adverse Events (Number of patients, n/N) Nu
Slide 19: RDEA594-105: Febuxostat Drug-Drug Interaction and PD Study
RDEA594-105: Phase 1 Febuxostat Drug-Drug Interaction and PD Study - Completed Population: 36 normal healthy volunteers with sUA ^ 6 mg/dL; 18 per dose panel Males and postmenopausal or sterile women 18 - 65 years of age, inclusive 2 panels with escalating doses of RDEA594 or placebo - 200 mg and 40
Slide 20: Combination of RDEA594 and Febuxostat Produced 60%-70% Reductions in sUA
Combination of RDEA594 and Febuxostat Produced 60% - 70% Reductions in sUA *Khosravan, et al. Clin Pharmacokinet 2006; 45 (8): 821-841 20 The combination arms are significantly different from febuxostat alone at all points from Days 9-15: p < 0.001 Mean percent sUA reduction observed with Krystexxa,
Slide 21: Overall Summary of Safety for RDEA594 Through Phase 2a
Overall Summary of Safety for RDEA594 Through Phase 2a Patients exposed to RDEA594 (either administration of RDEA594 or its prodrug, RDEA806): Healthy subjects and HIV pts ~360 for up to 14 days Gout patients ~ 40 for up to 28 days Control subjects ~ 88 21 Arm Discontinuations Due to AEs N (%) Serio
Slide 22: RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities
RDEA594 Phase 2 Program Focuses on Important Commercial Opportunities Phase 2b monotherapy dose-response, safety and efficacy study (n~140) Supports use in patients who are intolerant to allopurinol, inadequate responders to allopurinol, and first-line treatment Phase 2b allopurinol add-on study in
Slide 23: RDEA594 Phase 2b Monotherapy Dose-Response, Safety and Efficacy Study
RDEA594 Phase 2b Monotherapy Dose- Response, Safety and Efficacy Study - Enrollment Complete 21 days 2 weeks 4 weeks 2 weeks Population: gout patients with hyperuricemia (serum uric acid ^8 mg/dL) target of 140 patients in 4 treatment arms Duration: 8 wks: 2-wk run-in, 4-wk treatment, 2-wk follow-up
Slide 24: RDEA594 Phase 2b Allopurinol Add-On Combination Study
RDEA594 Phase 2b Allopurinol Add-On Combination Safety and Efficacy Study - Enrolling Dose selection based on sUA lowering with 200 mg RDEA594: 18 patients initially, including 12 patients randomized to RDEA594 and 6 patients randomized to placebo 75% of patients did not have sUA < 5 mg/dL after 14
Slide 25: Cancer MEK Program Licensed to Bayer HealthCare
Cancer 25 MEK program licensed to Bayer HealthCare on April 28, 2009 $35 million upfront license fee Payments could total $407 million, excluding royalties Low double-digit royalties on worldwide sales Ardea responsible for completing two dose-finding studies (expected completion to MTD in 1H10)
Slide 26: Financial Position Summary
Financial Position Summary Statement of Operations (In thousands, except per share data) Nine Months Ended Sept. 30, 2009 Revenue Operating expenses Other expense $ 14,681 38,527 (691) NET LOSS $(24,537) NET LOSS PER SHARE $(1.36) 18.5 million common shares outstanding Expect 2009 year-end cash bala
Slide 27: Near-Term Anticipated Milestones
Near-Term Anticipated Milestones Drug Candidate Event Date Date Gout Gout Gout Gout RDEA594 Phase 2a - Cohort 2 Allopurinol Combo Results Phase 2a - Cohort 2 Allopurinol Combo Results ? RDEA594 Febuxostat Combination Study Results Febuxostat Combination Study Results ? RDEA594 Phase 2b Monotherapy S